Liftstream is an executive search recruitment company in the life sciences sector
New Enterprise Associates backs veteran rare diseases executive team
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Boston Biotech, Cristina Csimma, Cydan Corporation, FDA, Jon Saxe, KLS Partners, LUM-001, Lumos Pharma, NEA, New England Associates, Orphan drugs, Prosensa, Rare Disease, Rick Hawkins, Sante Ventures, unmet medical needs
Leave a comment
Massachusetts biotech continues to excite with new investments
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Abingworth Management, BioPharma America, Biotechnology cluster, Boston, Brookside Capital, Cristina Csimma, Cydan, David Mott, Deerfield, DELPHI, Dicer Substrate siRNA, Dicerna Pharmaceuticals, drug delivery technologies, Duchenne Muscular Dystrophy, EDI200, Edimer Pharmaceuticals, EnCore™, exon skipping, Exportin-1, Forsite Capital Management, Genzyme, Inhibitors of Nuclear Export, innovation, investors, Karyopharm Therapeutics, Massachusetts, Neil Kirby, New Enterprise Associates, New Leaf Venture Partners, NEZ, Omega Funds, oncology market, Orphan Drug, Prosensa, RA Capital, Rare Disease, Sanofi, Series B, SR One, Third Rock Ventures, TKT, undruggable disease, Vertex Pharmaceuticals, X-linked Hypohidrotic Ectodermal Dysplasia, XLHED
Leave a comment